Hexarelin

Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHRP and one of the most potent growth hormone secretagogues ever developed. It produces the strongest acute GH release of any GHRP — surpassing GHRP-6, GHRP-2, and Ipamorelin — making it the compound of choice for researchers investigating maximal GH stimulation. What distinguishes hexarelin from other GHRPs, however, is not just its GH-releasing potency but its documented cardioprotective properties — an effect mediated through a non-GHS-R1a mechanism unique to this compound.

Hexarelin activates the GHS-R1a receptor with exceptionally high affinity, producing acute GH elevations of 10-20 fold above baseline — the highest of any peptide-based secretagogue. However, hexarelin also binds to CD36 (scavenger receptor class B member 3), a receptor expressed on cardiac myocytes and coronary vasculature. This CD36-mediated pathway produces cardioprotective effects independent of GH release: reduced cardiac fibrosis, improved left ventricular function, decreased infarct size following ischemic events, and anti-atherosclerotic activity through modulation of macrophage cholesterol efflux. These cardiac effects occur at doses lower than those needed for maximal GH release, suggesting the two activities can be separately optimized.

Research on hexarelin's GH-releasing properties documents the strongest acute response of any GHRP, but also the most pronounced desensitization. Continuous daily use at high doses leads to diminished GH response within 4-8 weeks due to receptor downregulation — a limitation not shared by Ipamorelin or GHRP-2 to the same degree. The cardiovascular research, however, shows sustained benefit: studies in ischemia-reperfusion models document reduced myocardial damage, preserved ejection fraction, and anti-fibrotic effects. This dual profile — potent but desensitization-prone GH release plus sustained cardiac protection — makes hexarelin a unique compound in the GHRP class.

Hexarelin is best suited for researchers investigating maximal GH stimulation in short-term protocols, cardioprotective peptide mechanisms, and cardiac recovery. Researchers using hexarelin for GH purposes should plan for cyclical dosing (4 weeks on, 2-4 weeks off) to manage receptor desensitization. Those primarily interested in its cardioprotective effects may use lower doses continuously.

Reconstitute with 2.5ml bacteriostatic water (yielding 2mg/ml). Administer via subcutaneous injection, 100-200mcg per dose, 1-3 times daily. Inject on an empty stomach. Hexarelin produces a noticeable appetite increase (between GHRP-2 and GHRP-6 in magnitude) and mild transient cortisol and prolactin elevation. Half-life is approximately 70 minutes. Store at 2-8C after reconstitution. Due to desensitization potential, cycle protocols rather than continuous use.

---

## Growth Factors